
SVRA
Healthcare · Biotechnology · $1.02B market cap
$4.64-0.08 (-1.7%)Nov 13, 4:19 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -1.7% over 90 days · 30-day revisions 1 up, 4 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2026 | After the close | -0.18 | -0.17 | +5.6% |
| Aug 11, 2026 | After the close | -0.14 | -0.16 | -14.3% |
| May 7, 2026 | Time not confirmed | -0.12 | -0.15 | -24.4% |
| Mar 13, 2026 | Before the open | -0.12 | -0.13 | -8.3% |
| Nov 12, 2025 | After the close | -0.13 | -0.14 | -7.7% |
| Aug 13, 2025 | Before the open | -0.12 | -0.14 | -16.7% |
| May 7, 2025 | Before the open | -0.13 | -0.12 | +6.3% |
| Mar 27, 2025 | Before the open | -0.11 | -0.13 | -18.2% |
| Nov 12, 2024 | Before the open | -0.11 | -0.11 | 0.0% |
| Aug 12, 2024 | After the close | -0.11 | -0.12 | -9.1% |
| May 9, 2024 | After the close | -0.10 | -0.11 | -10.0% |
| Mar 7, 2024 | After the close | -0.10 | -0.09 | +10.0% |
| Nov 9, 2023 | After the close | -0.07 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
| -0.10 |
| -42.9% |
| Aug 10, 2023 | After the close | -0.08 | -0.07 | +12.5% |
| May 15, 2023 | Before the open | -0.07 | -0.07 | 0.0% |
| Mar 30, 2023 | After the close | -0.07 | -0.07 | 0.0% |
| Nov 10, 2022 | After the close | -0.07 | -0.07 | 0.0% |
| Aug 11, 2022 | After the close | -0.06 | -0.06 | 0.0% |
| May 11, 2022 | After the close | -0.08 | -0.05 | +37.5% |
| Mar 30, 2022 | After the close | -0.07 | -0.07 | 0.0% |
| Nov 12, 2021 | Before the open | -0.09 | -0.07 | +22.2% |
| Aug 12, 2021 | After the close | -0.12 | -0.07 | +41.7% |
| May 13, 2021 | After the close | -0.09 | -0.13 | -44.4% |
| Mar 10, 2021 | Before the open | -0.10 | -0.23 | -130.0% |
| Nov 5, 2020 | After the close | -0.20 | -0.18 | +10.0% |
| Aug 6, 2020 | After the close | -0.20 | -0.16 | +20.0% |
| May 7, 2020 | After the close | -0.28 | -0.27 | +3.6% |
| Mar 12, 2020 | After the close | -0.33 | -0.28 | +15.2% |
| Nov 7, 2019 | After the close | -0.41 | -0.30 | +26.8% |
| Aug 8, 2019 | After the close | -0.41 | -0.38 | +7.3% |
| May 9, 2019 | After the close | -0.35 | -0.34 | +2.9% |
| Mar 13, 2019 | After the close | -0.36 | -0.29 | +19.4% |
| Nov 7, 2018 | After the close | -0.34 | -0.37 | -8.8% |
| Aug 9, 2018 | After the close | -0.37 | -0.38 | -2.7% |
| May 9, 2018 | After the close | -0.36 | -0.29 | +19.4% |
| Mar 14, 2018 | After the close | -0.26 | -0.23 | +11.5% |